Vaxart (VXRT) to Release Earnings on Thursday

Vaxart (OTCMKTS:VXRT) is projected to release its Q4 2025 resultson Thursday, March 12th. Analysts expect Vaxart to post earnings of ($0.08) per share and revenue of $35.95 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 12, 2026 at 4:30 PM ET.

Vaxart Stock Performance

OTCMKTS:VXRT opened at $0.74 on Friday. Vaxart has a 52 week low of $0.26 and a 52 week high of $0.84. The firm has a 50-day moving average price of $0.60 and a two-hundred day moving average price of $0.45. The firm has a market cap of $177.68 million, a price-to-earnings ratio of -3.21 and a beta of 1.17.

Hedge Funds Weigh In On Vaxart

A number of hedge funds and other institutional investors have recently made changes to their positions in VXRT. Marshall Wace LLP bought a new position in Vaxart during the second quarter valued at about $794,000. Jones Financial Companies Lllp raised its position in Vaxart by 276,364.7% in the first quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock worth $196,000 after acquiring an additional 478,111 shares during the period. Raymond James Financial Inc. boosted its stake in Vaxart by 16.9% in the second quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company’s stock valued at $107,000 after acquiring an additional 34,075 shares during the last quarter. Invesco Ltd. boosted its stake in Vaxart by 93.1% in the first quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock valued at $60,000 after acquiring an additional 70,568 shares during the last quarter. Finally, Goldman Sachs Group Inc. bought a new position in shares of Vaxart during the 1st quarter valued at approximately $31,000. 18.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised Vaxart to a “buy” rating in a report on Friday, January 23rd. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average target price of $2.00.

Vaxart Company Profile

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.